
Medical colleges accused of illegally jacking up fees
A group of medical students has come forward, accusing private medical colleges in Telangana of collecting unauthorised fees. They have called upon the National Medical Commission (NMC), the Telangana Admission and Fee Regulatory Committee (TAFRC), and the government to promptly intervene in what they describe as an 'illegal business.' One medical student from a private college stated that a representation had already been sent to the NMC regarding the unauthorised fee collection by an institution in Telangana. He claimed his college was reportedly charging Rs 11,55,000 per annum for five years under B-Category MBBS admissions, cumulatively amounting to Rs 57,75,000. This, he argued, is a direct violation of GO MS No 5, issued on 27 January 2022, and the fee structure approved by the TAFRC, which explicitly sets the total MBBS course fee at Rs 51,97,500, payable in five equal annual instalments of Rs 10,39,500. The student highlighted that the excess amount of Rs 5,77,500, equivalent to an additional six months' fee, places an unjust financial burden on students and their families.
The medico emphasised that such violations compromise the affordability and transparency of medical education. They sought immediate attention and corrective action from the concerned authorities, urging agencies to investigate this clear deviation from approved norms, direct the colleges to strictly adhere to the prescribed fee structure, and prevent arbitrary and unauthorised fee collections in the future. Despite several requisitions over the past two years, no action has been taken so far, the student added.
Interestingly, the TAFRC had issued a clarification in 2022, stating that the fee fixed by the committee for the entire MBBS course, which spans four years and is divided into nine semesters, was designed to alleviate the financial burden on students by being split into five equal instalments over the four-year course. The committee recommended that the fee should be collected at the beginning of each academic year in five equal instalments and that managements should not collect fees in advance. It was also clarified that candidates who were detained or failed during their course and continued their studies should not be charged fees again for that academic year, as they had already paid. The students are now appealing to the government to intervene and prevent them from being overcharged.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News18
an hour ago
- News18
Ayushman Bharat Scheme: Where And How To Complain If Hospital Denies Treatment
Last Updated: Over 41 crore Ayushman cards issued for free treatment up to Rs 5 lakh. Cardholders can complain if treatment is denied via helpline 14555 or the official portal The Ayushman Bharat Yojana was introduced to provide free medical treatment to underprivileged individuals across India. As of July 2025, more than 41 crore Ayushman cards have been issued under the Ayushman Bharat Pradhan Mantri Jan-Arogya Yojana, allowing eligible individuals to receive treatment worth up to Rs 5 lakh per year. Wide Network Of Hospitals The scheme includes a vast network of 31,466 empanelled hospitals nationwide, of which 14,194 are private institutions. Ayushman cardholders can avail themselves of treatment at any hospital listed under the scheme. What If A Hospital Refuses Treatment? Despite being on the panel, some hospitals may refuse to provide treatment, which goes against the scheme's rules. If the hospital has the necessary facilities for the illness in question, it is obligated to offer treatment to the cardholder. Refusal can result in government action, including removal from the panel. State-Specific Helplines Online Complaint Registration If your complaint remains unresolved via phone, you can submit it online through the official portal: Register Complaint Here Steps To Register A Complaint view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
&w=3840&q=100)

Business Standard
2 hours ago
- Business Standard
Govt panel starts drafting rules for refurbished medical device imports
An inter-departmental high-level committee of the central government has begun discussions on new rules to regulate the entry of refurbished or second-hand medical devices into India. Valued at Rs 1,500 crore, industry executives estimate that the pre-owned medical equipment market accounts for around 10 per cent of the total medical equipment industry in the country. Sources told Business Standard that while only a couple of meetings have taken place so far, the committee is reviewing data related to the pre-owned or refurbished devices market. Officials confirmed that the panel includes representatives from the Ministry of Health and Family Welfare, Directorate General of Health Services (DGHS), the Central Drugs Standard Control Organisation (CDSCO), the Department of Pharmaceuticals, and industry stakeholders. This follows a communication by CDSCO to the Principal Commissioner of Customs in January 2025, acknowledging that there was no specific regulation for refurbished devices under the Medical Devices Rules (MDR), 2017. 'MDR 2017 has a provision for import of medical devices and the requirements are well set for this. The regulation does not differentiate between new and refurbished medical devices,' a health ministry official said. Currently, such imports are allowed through no-objection certificates from an expert committee of the Ministry of Environment, Forest and Climate Change (MoEFCC). The approvals are limited to 38 high-end and high-value (HEHV) medical equipment items listed by the DGHS. Imports are subject to conditions such as ensuring that equipment has not been phased out in the exporting country, contains no hazardous materials, and has a residual life of at least seven years. 'Major points to be discussed by the committee may include the service time of second-hand devices eligible for import or allowing only very expensive, high-end critical care equipment,' an official said. Confirming the development, MoEFCC sources said that while existing MDR provisions do not cover refurbished equipment, the health ministry is drafting regulatory mechanisms to support ease of doing business in the sector. 'MoHFW has shared a draft proposal with MoEFCC for comments,' the person added. Pre-owned medical devices largely include robotic-assisted surgery systems, linear accelerators, and CT scanners, which help meet demand in Tier-II, Tier-III, Tier-IV cities and underserved areas. While proponents argue that refurbished alternatives provide affordable solutions for smaller cities, several lobby groups and domestic manufacturers have urged the ministry to stop unregulated imports of high-risk second-hand medical equipment citing patient safety concerns. The Patient Safety and Access Initiative of India Foundation (PSAIIF), a Delhi-based not-for-profit organisation, has also filed a public interest litigation in the Delhi High Court, raising concerns over the reliability of these devices and risks to patient safety.


Business Standard
2 hours ago
- Business Standard
Glenmark Pharma's US arm to launch Micafungin injection in the US market
Glenmark Pharmaceuticals announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, will launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), in the U.S. market this September. The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million. Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Marc Kikuchi, president & business head, North America said, We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need. Glenmarks Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication listed in Glenmarks approved label. All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmarks product is only approved for the indications listed in Glenmarks approved label and is not marketed for all RLD indications. IQVIA National Sales Perspectives: Retail & Non-Retail, June 2025. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip declined 1.38% to Rs 1,947.10 on the BSE.